|
|
| | 2-Pyridinecarboxamide, 4-[4-[[[[2-fluoro-5-[1,2,2,2-tetrafluoro-1-(trifluoromethyl)ethyl]phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- Basic information |
| Product Name: | 2-Pyridinecarboxamide, 4-[4-[[[[2-fluoro-5-[1,2,2,2-tetrafluoro-1-(trifluoromethyl)ethyl]phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- | | Synonyms: | 2-Pyridinecarboxamide, 4-[4-[[[[2-fluoro-5-[1,2,2,2-tetrafluoro-1-(trifluoromethyl)ethyl]phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-;APS6-45;APS6-45,calibrated,signaling,TCI,Inhibitor,APS-6-45,APS645,Carcinoma,Thyroid,Ras,antitumor,Medullary,MAPK,APS6 45,tumor,inhibit;4-(4-(3-(2-Fluoro-5-(perfluoropropan-2-yl)phenyl)ureido)phenoxy)-N-methylpicolinamide;APS6-45, 10 mM in DMSO;4-[4-[[2-fluoro-5-(1,1,1,2,3,3,3-heptafluoropropan-2-yl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide;APS6-45 ,S3493;N-(2-fluoro-4-(1,1,2,2,3,3,3-heptafluoropropyl)phenyl)-N'-(4-((5-(methylcarbamoyl)pyridin-3-yl)oxy)phenyl)urea | | CAS: | 2188236-41-9 | | MF: | C23H16F8N4O3 | | MW: | 548.39 | | EINECS: | | | Product Categories: | | | Mol File: | 2188236-41-9.mol | ![2-Pyridinecarboxamide, 4-[4-[[[[2-fluoro-5-[1,2,2,2-tetrafluoro-1-(trifluoromethyl)ethyl]phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- Structure](CAS/20200611/GIF/2188236-41-9.gif) |
| | 2-Pyridinecarboxamide, 4-[4-[[[[2-fluoro-5-[1,2,2,2-tetrafluoro-1-(trifluoromethyl)ethyl]phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- Chemical Properties |
| solubility | DMF: 5 mg/ml DMSO: 10 mg/ml Ethanol: 10 mg/ml | | form | Solid | | color | Off-white to light yellow |
| | 2-Pyridinecarboxamide, 4-[4-[[[[2-fluoro-5-[1,2,2,2-tetrafluoro-1-(trifluoromethyl)ethyl]phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- Usage And Synthesis |
| Uses | APS6-45 is an orally active tumor-calibrated inhibitor (TCI). APS6-45 inhibits RAS/MAPK signaling and exhibits antitumor activity[1]. | | in vivo | APS6-45 (10 mg/kg; p.o. daily for 30 d) inhibits growth of TT tumors in mice and does not affect body weight[1].
APS6-45 (0.1-160 mg/kg; a single p.o.) does not cause detectable toxic effects in mice[1].
APS6-45 (20 mg/kg; a single p.o.) exhibits long half-life (5.6 h), Cmax (9.7 μM) and AUC0-24 (123.7 μMh) in mice[1]. | Animal Model: | Female nude mice (6 weeks) are implanted with TT cells[1] | | Dosage: | 10 mg/kg | | Administration: | P.o. daily for 30 days | | Result: | Led to partial or complete responses in 75% and was well tolerated. |
| Animal Model: | Male ICR mice (6 weeks of age)[1] | | Dosage: | 20 mg/kg (Pharmacokinetic Analysis) | | Administration: | A single p.o. | | Result: | T1/2=5.6 h, Cmax=9.7 μM, AUC0-24=123.7 μMh. |
| | References | [1] Sonoshita M, et, al. A whole-animal platform to advance a clinical kinase inhibitor into new disease space. Nat Chem Biol. 2018 Mar;14(3):291-298. DOI:10.1038/nchembio.2556 |
| | 2-Pyridinecarboxamide, 4-[4-[[[[2-fluoro-5-[1,2,2,2-tetrafluoro-1-(trifluoromethyl)ethyl]phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- Preparation Products And Raw materials |
|